Eleven Biotherapeutics (NASDAQ: EBIO) reported Q2 EPS of ($0.36), $0.08 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $114 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.